StockSelector.com
  Research, Select, & Monitor Friday, August 23, 2019 7:21:26 AM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Ligand Pharmaceuticals, Inc.$95.90($1.58)(1.62%)

  Quote | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

Ligand Pharmaceuticals, Inc. has an overall rank of 756 out of 7062 stocks based on 13 positive rankings and 7 negative rankings.

Positive Rankings
Historic EPS Growth
Ligand Pharmaceuticals rank is 56
Low/Rising MACD
The MACD remains negative, but is rising... suggesting a possible near-term correction. Of companies with a negative, but rising MACD, Ligand Pharmaceuticals is ranked 92.
Highest Cash Growth
Ligand Pharmaceuticals rank is 101
Highest Net Margin
Ligand Pharmaceuticals rank is 114
Historic Revenue Growth
Ligand Pharmaceuticals rank is 289
SSValue
The StockSelector Value for Ligand Pharmaceuticals is $317.41. The StockSelector Value assumes the market consistently prices a stock around a given PE ratio and, therefore, multiplies the average PE (using forward earnings estimates) over the past three years by future earnings estimates. Among companies with a StockSelector Value above the current stock price, Ligand Pharmaceuticals is ranked 360.
Target Prices
The average analysts' target price is $131.00 for Ligand Pharmaceuticals using target prices set or adjusted within the past 90 days. Among companies with recent target prices and with the average above the current stock price, Ligand Pharmaceuticals is ranked 371.
Highest ROE
Ligand Pharmaceuticals rank is 511
Highest ROA
Ligand Pharmaceuticals rank is 521
Low vPut/Call
Ligand Pharmaceuticals has a low Put/Call ratio of 0.30 on active options expiring within the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Ligand Pharmaceuticals is ranked 569.
10 Day Gain
Ligand Pharmaceuticals rank is 899
Up EPS Surprise
Ligand Pharmaceuticals beat the consensus earnings estimate when it last reported quarterly earnings.
Debt-to-Equity
Ligand Pharmaceuticals rank is 2409
Negative Rankings
Negative Stoch Cross
Ligand Pharmaceuticals rank is 4
Negative Revenue Estimate
Ligand Pharmaceuticals rank is 55
High Put/Call
Ligand Pharmaceuticals has a high Put/Call ratio of 1.88 on all open interest of options expiring in the next 90 days. A high put-to-call ratio indicates there are more bearish investors than bullish investors for the stock. Among companies with a high Put/Call Ratio, Ligand Pharmaceuticals is ranked 335.
Price-to-Sales
Ligand Pharmaceuticals rank is 480
Down Estimate Revision
During the past month, the consensus earnings estimate for the current year and next year have decreased by a combined (3.70%). Among companies that have had their estimates lowerec within the past month, Ligand Pharmaceuticals is ranked 556.
90 Day Loss
Ligand Pharmaceuticals rank is 1082
Price-to-Book
Ligand Pharmaceuticals rank is 1277







Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2019 StockSelector.com. All rights reserved.